Schema · Resurrect

Schema

27,619 programs· FDA-approved drugs hidden

1/461

Molecule	Phase	Sponsor	Stopped	N
veliparib Ovarian Cancer Business / strategicNCT02470585	Phase 3	AbbVie	2023	1,140	—	69	89
Follicle Activation Cystic Fibrosis Business / strategicNCT03447262	Phase 3	Vertex Pharmaceuticals Incorporated	2020	484	—	82	88
folfirinox Pancreatic Cancer Business / strategicNCT01836432	Phase 3	NewLink Genetics Corporation	2017	302	—	77	85
evolocumab Dyslipidemia Business / strategicNCT03080935	Phase 3	Amgen	2022	1,600	—	70	85
PI-88 Cancer Business / strategicNCT01402908	Phase 3	Cellxpert Biotechnology Corp.	2015	520	—	69	85
ataluren Muscular Dystrophy, Duchenne Business / strategicNCT02090959	Phase 3	PTC Therapeutics	2018	219	—	67	85
florbetapir Cardiac Amyloidosis Accrual failureNCT03040427	Phase 4	The Cleveland Clinic	2019	12	—	86	84
N-Acetyl Cysteine (NAC) Acute Liver Failure Funding lostNCT00896025	Phase 4	University of Texas Southwestern Medical Center	2016	255	—	79	84
ONC201 Glioblastoma Business / strategicNCT02525692	Phase 2	Jazz Pharmaceuticals	2023	84	—	73	84
Ursodeoxycholic Acid Liver Cirrhosis, Biliary Business / strategicNCT00550862	Phase 2	Intercept Pharmaceuticals	2010	165	—	70	84
Tiomolibdic acid Wilson Disease Business / strategicNCT03403205	Phase 3	Alexion Pharmaceuticals, Inc.	2023	214	—	69	84
Endeavor, Medtronic Myocardial Infarction Accrual failureNCT00422565	Phase 4	Seung-Jung Park	2008	328	—	88	83
infigratinib Upper Tract Urothelial Carcinomas Business / strategicNCT04197986	Phase 3	QED Therapeutics, a BridgeBio company	2023	39	—	87	83
Radiotherapy Soft Tissue Sarcoma of Members Accrual failureNCT00870701	Phase 3	Institut Claudius Regaud	2017	77	—	86	83
Radiotherapy Lymphoma Accrual failureNCT00014326	Phase 3	European Organisation for Research and Treatment of Cancer - EORTC	2012	204	—	82	83
melflufen Relapsed Multiple Myeloma Business / strategicNCT04649060	Phase 3	Oncopeptides AB	2022	54	—	80	83
Esophagectomy Esophageal Squamous Cell Carcinoma Accrual failureNCT01740375	Phase 3	Asan Medical Center	2017	486	—	77	83
sitravatinib Urothelial Carcinoma Business / strategicNCT03606174	Phase 2	Mirati Therapeutics Inc.	2022	260	—	71	83
alvocidib Acute Myeloid Leukemia Accrual failureNCT02520011	Phase 2	Sumitomo Pharma America, Inc.	2020	104	—	70	83
Ferrous sulphate Contraception Business / strategicNCT01656434	Phase 3	Organon and Co	2014	3,173	—	69	83
efpeglenatide Type 2 Diabetes Mellitus Business / strategicNCT03496298	Phase 3	Sanofi	2020	4,076	—	69	83
FG-3019 Idiopathic Pulmonary Fibrosis Business / strategicNCT04419558	Phase 3	Kyntra Bio	2023	372	—	65	83
Inhaled dry powder treprostinil Pulmonary Hypertension Business / strategicNCT03496623	Phase 3	United Therapeutics	2022	188	—	86	82
evolocumab Primary Hypercholesterolemia Business / strategicNCT03433755	Phase 3	Amgen	2020	259	—	86	82
Percutaneous Coronary Intervention Coronary Artery Disease Accrual failureNCT00326196	Phase 4	US Department of Veterans Affairs	2012	198	—	84	82
BIKTARVY® HIV-1-infection Accrual failureNCT03532425	Phase 4	University of Alberta	2020	28	—	84	82
Factor VIII Hemophilia A Business / strategicNCT01376700	Phase 3	Baxalta now part of Shire	2012	22	—	84	82
lumacaftor-ivacaftor Cystic Fibrosis Accrual failureNCT02823470	Phase 4	Vertex Pharmaceuticals Incorporated	2017	24	—	84	82
liposomal doxorubicin Ovarian Neoplasms Business / strategicNCT00350948	Phase 3	Telik	2008	244	—	82	82
Cilengitide Adult Giant Cell Glioblastoma Accrual failureNCT00112866	Phase 2	National Cancer Institute (NCI)	2009	30	—	82	82
masitinib Multiple Myeloma Business / strategicNCT01470131	Phase 3	AB Science	2017	147	—	82	82
efpeglenatide Type 2 Diabetes Mellitus Business / strategicNCT03684642	Phase 3	Sanofi	2020	908	—	75	82
reteplase Catheter Occlusion Accrual failureNCT03594175	Phase 3	Chiesi Farmaceutici S.p.A.	2023	462	—	73	82
Resistant Starch COVID-19 Accrual failureNCT04342689	Phase 2/3	Yale University	2021	226	—	71	82
copanlisib Lymphoma, Non-Hodgkin Business / strategicNCT02626455	Phase 3	Bayer	2023	551	—	69	82
Brachytherapy Breast Cancer Funding lostNCT00214149	Phase 2	University of Wisconsin, Madison	2010	127	—	69	82
Transcutaneous Electric Nerve Stimulation Low Back Pain Accrual failureNCT00290238	Phase 4	RS Medical	2008	122	—	86	81
Practice Guidelines as Topic Hepatitis C, Chronic Accrual failureNCT03207399	Phase 4	Duke University	2019	1	—	86	81
Preimplantation Diagnosis Preimplantation Gentic Screening (PGS) Accrual failureNCT01194531	Phase 4	Natera, Inc.	2013	59	—	86	81
ONC201 Endometrial Cancer Recurrent Business / strategicNCT03485729	Phase 2	Jazz Pharmaceuticals	2023	27	—	85	81
Academic detailing Cervical Cancer OperationalNCT00629993	Phase 4	Columbia University	2010	282	—	82	81
inclacumab Sickle Cell Disease Accrual failureNCT04927247	Phase 3	Pfizer	2023	72	—	82	81
daclatasvir Chronic Hepatitis C Infection Business / strategicNCT01866930	Phase 3	Bristol-Myers Squibb	2015	453	—	81	81
Cediranib Glioblastoma Accrual failureNCT01310855	Phase 2	University College, London	2014	38	—	81	81
Amoxicillin-Clavulanate, 10 days Neutropenia, Febrile Accrual failureNCT03003273	Phase 3	All India Institute of Medical Sciences	2018	142	—	79	81
masitinib Gastrointestinal Stromal Tumors Business / strategicNCT00812240	Phase 3	AB Science	2018	335	—	77	81
Chemotherapy, Adjuvant Metastatic Cancer Accrual failureNCT00002899	Phase 3	European Organisation for Research and Treatment of Cancer - EORTC	2012	340	—	77	81
177Lu-PSMA-617 Metastatic Castration Resistant Prostate Cancer Accrual failureNCT03042312	Phase 2	Endocyte	2020	71	—	77	81
formerly as RP5307 Chronic Lymphocytic Leukemia Business / strategicNCT02742090	Phase 2	TG Therapeutics, Inc.	2021	51	—	76	81
MD1003 Multiple Sclerosis Business / strategicNCT02936037	Phase 3	MedDay Pharmaceuticals SA	2020	642	—	75	81
Inhaled Insulin Diabetes Mellitus, Type 2 Business / strategicNCT00437489	Phase 4	Pfizer	2007	49	—	88	80
Radiotherapy Breast Cancer Accrual failureNCT00005983	Phase 3	SWOG Cancer Research Network	2005	98	—	86	80
Quetiapine XR Bipolar Disorder Funding lostNCT00746421	Phase 4	Emory University	2012	32	—	86	80
Dequalinium Bacterial Vaginosis Accrual failureNCT05788991	Phase 4	Medinova AG	2022	151	—	84	80
Contrast Enhanced Ultrasound (CEUS) Liver Biopsy Accrual failureNCT03040323	Phase 4	Indiana University	2018	83	—	84	80
Efpeglenatide SAR439977 Type 2 Diabetes Mellitus Business / strategicNCT03713684	Phase 3	Sanofi	2021	370	—	81	80
Tiomolibdic acid Wilson Disease Business / strategicNCT05047523	Phase 3	Alexion Pharmaceuticals, Inc.	2023	40	—	81	80
Efpeglenatide SAR439977 Type 2 Diabetes Mellitus Business / strategicNCT03770728	Phase 3	Sanofi	2020	312	—	81	80
fotemustine Intraocular Melanoma Accrual failureNCT00110123	Phase 3	European Organisation for Research and Treatment of Cancer - EORTC	2012	171	—	80	80
Transplantation Acute Myocardial Infarction Accrual failureNCT00350766	Phase 2/3	Ministry of Health, Brazil	2014	166	—	77	80